CA2449402C - Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases - Google Patents
Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases Download PDFInfo
- Publication number
- CA2449402C CA2449402C CA002449402A CA2449402A CA2449402C CA 2449402 C CA2449402 C CA 2449402C CA 002449402 A CA002449402 A CA 002449402A CA 2449402 A CA2449402 A CA 2449402A CA 2449402 C CA2449402 C CA 2449402C
- Authority
- CA
- Canada
- Prior art keywords
- group
- optionally substituted
- aryl
- compound according
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0113708A GB0113708D0 (en) | 2001-06-06 | 2001-06-06 | Chemical compounds |
| GB0113708.2 | 2001-06-06 | ||
| US31150201P | 2001-08-10 | 2001-08-10 | |
| US60/311,502 | 2001-08-10 | ||
| PCT/GB2002/002517 WO2002098426A1 (en) | 2001-06-06 | 2002-06-05 | Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2449402A1 CA2449402A1 (en) | 2002-12-12 |
| CA2449402C true CA2449402C (en) | 2009-08-11 |
Family
ID=26246159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002449402A Expired - Fee Related CA2449402C (en) | 2001-06-06 | 2002-06-05 | Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7211586B2 (enExample) |
| EP (1) | EP1392306B1 (enExample) |
| JP (1) | JP4583751B2 (enExample) |
| AT (1) | ATE383858T1 (enExample) |
| AU (1) | AU2002302783B2 (enExample) |
| CA (1) | CA2449402C (enExample) |
| DE (1) | DE60224664T2 (enExample) |
| DK (1) | DK1392306T3 (enExample) |
| ES (1) | ES2296926T3 (enExample) |
| IL (1) | IL159203A0 (enExample) |
| MX (1) | MXPA03009660A (enExample) |
| PT (1) | PT1392306E (enExample) |
| WO (1) | WO2002098426A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004287875B2 (en) | 2003-11-05 | 2011-06-02 | Bausch + Lomb Ireland Limited | Modulators of cellular adhesion |
| WO2005070891A2 (en) * | 2004-01-23 | 2005-08-04 | Amgen Inc | Compounds and methods of use |
| JP2006056830A (ja) * | 2004-08-20 | 2006-03-02 | Dai Ichi Seiyaku Co Ltd | ２−アリールアミノベンゾオキサゾール誘導体 |
| MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| US7402596B2 (en) * | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| SI1881823T1 (sl) | 2005-05-17 | 2015-04-30 | Sarcode Bioscience Inc. | Sestavki in postopki za zdravljenje bolezni oäśesa |
| WO2007050124A1 (en) * | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| CA2702984C (en) | 2007-10-19 | 2017-04-11 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
| CN102065694A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂 |
| WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| EP3632444A3 (en) * | 2008-04-15 | 2020-08-26 | SARcode Bioscience Inc. | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| EP2276508A4 (en) * | 2008-04-15 | 2011-12-28 | Sarcode Bioscience Inc | ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM |
| WO2010093535A1 (en) * | 2009-02-12 | 2010-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| KR102066297B1 (ko) * | 2011-10-14 | 2020-01-14 | 암비트 바이오사이언시즈 코포레이션 | 헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도 |
| CA2862807A1 (en) * | 2011-11-30 | 2013-06-06 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
| EP2877465A4 (en) | 2012-07-25 | 2016-05-11 | Sarcode Bioscience Inc | LFA-1 HEMMER AND POLYMORPH THEREOF |
| US20190389836A1 (en) * | 2017-01-30 | 2019-12-26 | Biogen Ma Inc. | Nrf2 activator |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| CN114727974A (zh) | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| WO2022169985A1 (en) | 2021-02-03 | 2022-08-11 | Eikonizo Therapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| WO2023287241A1 (ko) * | 2021-07-15 | 2023-01-19 | 주식회사 휴사이온 | 신규한 벤즈옥사졸아민 유도체 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| AU2023250964A1 (en) | 2022-04-08 | 2024-11-07 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236934A (en) * | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| JP3676677B2 (ja) * | 1998-06-30 | 2005-07-27 | ファイザー・プロダクツ・インク | 炎症性疾患、自己免疫疾患および呼吸疾患の治療において有用なｖｌａ−４依存性細胞結合の非ペプチジル阻害薬 |
| PT1114028E (pt) * | 1998-08-26 | 2007-02-28 | Aventis Pharma Ltd | Aza-biciclos moduladores da inibição da adesão celular |
| EP1214292B1 (en) * | 1999-09-24 | 2007-06-13 | Genentech, Inc. | Tyrosine derivatives |
-
2002
- 2002-06-05 JP JP2003501465A patent/JP4583751B2/ja not_active Expired - Fee Related
- 2002-06-05 AU AU2002302783A patent/AU2002302783B2/en not_active Ceased
- 2002-06-05 EP EP02730462A patent/EP1392306B1/en not_active Expired - Lifetime
- 2002-06-05 ES ES02730462T patent/ES2296926T3/es not_active Expired - Lifetime
- 2002-06-05 WO PCT/GB2002/002517 patent/WO2002098426A1/en not_active Ceased
- 2002-06-05 IL IL15920302A patent/IL159203A0/xx unknown
- 2002-06-05 DE DE60224664T patent/DE60224664T2/de not_active Expired - Lifetime
- 2002-06-05 DK DK02730462T patent/DK1392306T3/da active
- 2002-06-05 AT AT02730462T patent/ATE383858T1/de not_active IP Right Cessation
- 2002-06-05 CA CA002449402A patent/CA2449402C/en not_active Expired - Fee Related
- 2002-06-05 PT PT02730462T patent/PT1392306E/pt unknown
- 2002-06-05 MX MXPA03009660A patent/MXPA03009660A/es unknown
-
2003
- 2003-11-18 US US10/715,662 patent/US7211586B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002302783B2 (en) | 2006-11-16 |
| US20040122047A1 (en) | 2004-06-24 |
| WO2002098426A1 (en) | 2002-12-12 |
| DE60224664D1 (de) | 2008-03-06 |
| IL159203A0 (en) | 2004-06-01 |
| JP4583751B2 (ja) | 2010-11-17 |
| ATE383858T1 (de) | 2008-02-15 |
| ES2296926T3 (es) | 2008-05-01 |
| EP1392306A1 (en) | 2004-03-03 |
| EP1392306B1 (en) | 2008-01-16 |
| MXPA03009660A (es) | 2004-04-02 |
| CA2449402A1 (en) | 2002-12-12 |
| PT1392306E (pt) | 2008-03-07 |
| JP2005500276A (ja) | 2005-01-06 |
| DE60224664T2 (de) | 2009-01-08 |
| DK1392306T3 (da) | 2008-05-19 |
| US7211586B2 (en) | 2007-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1183254B1 (en) | Substituted bicyclic heteroaryl compounds as integrin antagonists | |
| EP1392306B1 (en) | Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases | |
| AU754557B2 (en) | Aza-bicycles which modulate the inhibition of cell adhesion | |
| AU2002302783A1 (en) | Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases | |
| US6593354B2 (en) | Substituted benzoxazole compounds | |
| CA2401441C (en) | Indane derivatives | |
| US20040006056A1 (en) | Substituted alkanoic acids | |
| CA2372836C (en) | Substituted pyrrolidines as cell adhesion inhibitors | |
| JP4754691B2 (ja) | 細胞接着の阻害を調節する、アザ−ビシクロ化合物 | |
| JP2002544192A (ja) | 置換ピロリジン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20130605 |